Rituxan

E46089

CD20-directed cytolytic antibody biologic drug chimeric monoclonal antibody monoclonal antibody

Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (5)

Label	Occurrences
rituximab	10
Rituxan canonical	5
Ocrevus	1
Truxima	1
obinutuzumab	1

Statements (52)

Predicate	Object
instanceOf	CD20-directed cytolytic antibody ⓘ biologic drug ⓘ chimeric monoclonal antibody ⓘ monoclonal antibody ⓘ
ATCCode	L01FA01 ⓘ
combinationRegimen	R-CHOP ⓘ
commonAdverseEffect	chills ⓘ fever ⓘ infections ⓘ infusion-related reactions ⓘ neutropenia ⓘ
contraindicatedIn	known severe hypersensitivity to rituximab ⓘ
developedBy	Biogen ⓘ Genentech ⓘ
firstApprovedBy	Food and Drug Administration ⓘ surface form: U.S. Food and Drug Administration
firstApprovedYear	1997 ⓘ
hasBiosimilar	Riabni ⓘ Ruxience ⓘ Rituxan self-linksurface differs ⓘ surface form: Truxima
hasBlackBoxWarning	hepatitis B virus reactivation ⓘ infusion reactions ⓘ progressive multifocal leukoencephalopathy ⓘ severe mucocutaneous reactions ⓘ
hasDrugClass	antineoplastic agent ⓘ immunosuppressive agent ⓘ
hasGenericName	rituximab ⓘ
hasINN	Rituxan self-linksurface differs ⓘ surface form: rituximab
hasMoleculeType	IgG1 kappa monoclonal antibody ⓘ
indicatedFor	chronic lymphocytic leukemia ⓘ diffuse large B-cell lymphoma ⓘ follicular lymphoma ⓘ granulomatosis with polyangiitis ⓘ microscopic polyangiitis ⓘ non-Hodgkin lymphoma ⓘ pemphigus vulgaris ⓘ rheumatoid arthritis ⓘ
isChimericOf	human antibody ⓘ mouse antibody ⓘ
marketedBy	Biogen ⓘ Genentech ⓘ
mechanismOfAction	binds CD20 on B cells ⓘ induces B-cell lysis ⓘ induces apoptosis of B cells ⓘ mediates antibody-dependent cellular cytotoxicity ⓘ mediates complement-dependent cytotoxicity ⓘ
oftenUsedWith	cyclophosphamide ⓘ doxorubicin ⓘ prednisone ⓘ vincristine ⓘ
routeOfAdministration	intravenous infusion ⓘ
targets	B lymphocytes ⓘ CD20 protein ⓘ

Referenced by (18)

Full triples — surface form annotated when it differs from this entity's canonical label.

Genentech → notableProduct → Rituxan ⓘ

Roche → product → Rituxan ⓘ

this entity surface form: Ocrevus

Rituxan → hasINN → Rituxan self-linksurface differs ⓘ